Overview: What “Duration” Means
The duration of ibogaine treatment can refer to several different timeframes: the acute psychoactive experience, the medically important post-acute period, the persistence of noribogaine, the suppression of opioid withdrawal, the reduction of craving, or longer-term behavioral outcomes.[1][2]
- Onset: effects are often reported within roughly 30 minutes to 3 hours after oral dosing, although timing varies by formulation, dose, food intake, and metabolism.[1][2]
- Acute visionary phase: the most intense psychoactive effects are commonly described as lasting about 4–12 hours, with some clinical descriptions placing the broader active session at 12–36 hours.[2][3]
- Residual phase: ataxia, fatigue, insomnia, sensitivity to stimulation, and prolonged introspection may last 24–72 hours after administration.[2][4]
- Therapeutic window: withdrawal relief and craving reduction may persist beyond the acute experience, but durability is variable and depends strongly on aftercare, medical context, and relapse-prevention support.[5][6]
Ibogaine is not an approved treatment for substance use disorder in the United States, and it carries serious cardiac risks that make duration clinically important, especially during the first 24–72 hours after dosing.[7]
Typical Acute Timeline
Ibogaine is often described as producing a multi-stage experience rather than a short psychedelic session.[1] Clinical and observational reports commonly divide the experience into onset, visionary, evaluative or introspective, and residual phases.[2][3]
- Onset, about 30 minutes–3 hours: early effects may include nausea, dizziness, auditory or visual changes, and reduced coordination.[1][2]
- Visionary phase, about 4–12 hours: many people report closed-eye imagery, autobiographical memory review, dream-like scenes, and reduced ability to move safely.[1][3]
- Evaluative phase, about 8–24 hours or longer: the intense imagery often diminishes, while wakefulness, reflection, emotional processing, and physical impairment may continue.[2][3]
- Residual phase, about 24–72 hours: sleep disruption, ataxia, weakness, tremor, light sensitivity, and continued psychological processing are commonly reported in clinical descriptions.[2][4]
The acute timeline is dose-dependent, and larger “flood dose” protocols used in some addiction-treatment settings generally last longer and require more intensive monitoring than low-dose or non-flood protocols.[2][4]
Why Effects Can Last Beyond the Trip
Ibogaine’s duration is partly explained by its conversion in the liver to noribogaine, an active metabolite that persists after the parent compound’s most intense psychoactive effects have declined.[1][2] Noribogaine is commonly discussed as a contributor to longer anti-withdrawal, anti-craving, and mood-related effects, although the exact relationship between blood levels and clinical outcomes remains incompletely established.[2][4]
Ibogaine and noribogaine interact with multiple receptor systems, including opioid, glutamatergic, serotonergic, nicotinic, and reward-circuit pathways.[1][7] These overlapping mechanisms may help explain why reported effects can include withdrawal suppression, reduced craving, altered mood, and an unusually long post-acute psychological state compared with many other psychoactive substances.[2][5]
Genetic and medication-related variation in CYP2D6 metabolism may influence exposure to ibogaine and noribogaine, which is one reason medical screening and medication review are considered central to safer treatment protocols.[4][7]
Opioid Withdrawal and Craving Duration
The most consistently reported short-term effect of ibogaine in humans is rapid reduction of opioid withdrawal signs and symptoms.[2][3] In a 1999 case series by Alper and colleagues, many opioid-dependent participants had marked reductions in objective withdrawal signs within 24 hours after ibogaine administration, although the study was uncontrolled and did not establish long-term efficacy.[3]
In a 12-month observational study by Noller, Frampton, and Yazar-Klosinski, opioid withdrawal and craving measures decreased after legally available ibogaine treatment in New Zealand, but long-term abstinence was not universal.[2] In the Mexico-based observational study by Brown and Alper, participants reported reduced opioid withdrawal and drug use after treatment, with strongest effects early in follow-up and variable persistence across later months.[5]
Withdrawal suppression may last through the acute detoxification period for some people, but withdrawal can return or persist, especially when a person has been using long-acting opioids such as methadone or buprenorphine.[2][5] Craving reduction is often described for days to weeks and sometimes months, but observational studies show that relapse remains common without structured continuing care.[5][6]
For a deeper review of this indication, see Ibogaine for Opioid Addiction and Ibogaine Treatment.[2][5]
Longer-Term Substance Use and Psychological Outcomes
Longer-term benefits after ibogaine are harder to interpret than acute withdrawal effects because most human studies are observational, retrospective, small, or based on self-report.[2][5] Reported outcomes range from brief interruption of use to months of reduced craving or abstinence, but ibogaine should not be described as a reliable cure for addiction.[5][6]
In a retrospective Brazilian study by Schenberg and colleagues, people treated with ibogaine in a psychotherapy-associated context reported longer abstinence periods after treatment, and multiple sessions were associated with longer reported abstinence than single sessions.[6] Because the study was retrospective and lacked random assignment, it cannot prove that ibogaine alone caused the reported abstinence improvements.[6]
Psychological effects sometimes described after ibogaine include autobiographical memory review, insight into trauma or compulsive behavior, and a sense of “reset,” but the durability of these subjective effects depends on integration, psychotherapy, environment, and relapse-prevention planning.[1][6] Related pages include Ibogaine Benefits, Ibogaine Therapy, and Ibogaine Uses.[1][6]
TBI, PTSD, Depression, and Mood-Related Duration
Recent interest in ibogaine has expanded beyond addiction to neuropsychiatric symptoms, including traumatic brain injury, PTSD, depression, anxiety, and cognitive complaints.[8] In a 2024 open-label Nature Medicine study of U.S. Special Operations Forces veterans, magnesium–ibogaine therapy was associated with improvements in disability, PTSD, depression, anxiety, and cognition measured at one month.[8]
The veteran study used medical monitoring and magnesium in a controlled clinical setting, and its open-label design means placebo effects, expectancy, selection factors, and concurrent care cannot be excluded.[8] The findings suggest possible effects lasting at least one month in a specific population, but they do not establish ibogaine as an approved or proven treatment for TBI, PTSD, depression, or anxiety.[8]
For condition-specific discussion, see Ibogaine for TBI, Ibogaine for PTSD, and Ibogaine Treatment for Depression and Anxiety.[8]
In an uncontrolled Stanford follow-up of special operations veterans, improvements in PTSD, depression and anxiety after a single treatment were largely maintained at one year, although most participants also used other psychedelics or therapies during that time.[10]
Factors That Change How Long Effects Last
Ibogaine duration varies substantially between individuals, and the same nominal dose can produce different intensity, duration, and risk profiles.[2][4]
- Dose and formulation: higher total doses and flood-dose protocols generally produce longer and more intense acute effects than lower-dose approaches.[1][4]
- Opioid type: people dependent on long-acting opioids may have more prolonged or incomplete withdrawal relief than people using shorter-acting opioids.[2][5]
- Metabolism: CYP2D6 variation and drug interactions can change ibogaine and noribogaine exposure, which may affect duration and toxicity risk.[4][7]
- Medical status: liver disease, electrolyte abnormalities, bradycardia, cardiac disease, and interacting medications can increase the safety risk during the treatment window.[7][9]
- Aftercare: psychotherapy, addiction medicine follow-up, stable housing, peer support, and relapse-prevention planning can influence whether short-term effects translate into longer-term benefit.[5][6]
People evaluating treatment programs should review Ibogaine Treatment Centers, How to Get Ibogaine Treatment Safely, and Ibogaine Treatment Cost.[7][9]
Safety Window: Why the First 24–72 Hours Matter
The same prolonged duration that makes ibogaine clinically interesting also extends the period of medical risk.[4][7] The major concern is cardiac toxicity, particularly QT prolongation and potentially fatal arrhythmias.[7][9]
A prospective clinical study by König and colleagues reported clinically important QTc prolongation after ibogaine, supporting the need for ECG monitoring during and after dosing.[4] A review by Koenig and Hilber described hERG potassium-channel inhibition and other cardiac mechanisms as plausible contributors to ibogaine-associated arrhythmia risk.[7]
Alper and colleagues reviewed deaths temporally associated with ibogaine ingestion and found that many cases involved comorbidities, concurrent substances, or other risk factors, with deaths often occurring in the acute or post-acute window.[9] Medical screening commonly focuses on ECG findings, electrolytes such as potassium and magnesium, liver function, medication interactions, psychiatric risk, and recent substance use.[4][7]
After opioid detoxification, tolerance can fall rapidly, and relapse to a previous opioid dose can increase overdose risk.[5] This risk is one reason ibogaine should be viewed as a possible transition or interruption intervention rather than a complete treatment plan.[5][6] For a detailed safety review, see Ibogaine Side Effects.[7][9]
Legality, Access, and Treatment Context
In the United States, ibogaine is listed as a Schedule I controlled substance and has no FDA-approved medical use. Because it is unapproved or illegal in many jurisdictions, some people travel to countries where clinics operate under different legal or regulatory conditions.[1]
Legal access and clinical oversight vary widely by country, and differences in screening, monitoring, emergency preparedness, and aftercare can affect both safety and the durability of treatment effects.[2][7] Relevant country and clinic guides include Ibogaine Legality by Country, Ibogaine Treatment in Mexico, and Where to Get Ibogaine Treatment.[1]
For opioid use disorder, evidence-based medications such as methadone, buprenorphine, and extended-release naltrexone have stronger regulatory support and clinical evidence than ibogaine.[5] Ibogaine may be most plausibly framed as a high-risk, medically complex intervention that can create a short-term window for change when followed by structured addiction care.[2][5]